Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT00781612
Title A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.

Advanced Solid Tumor


Ado-trastuzumab emtansine + Trastuzumab

Ado-trastuzumab emtansine + Paclitaxel

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine + Docetaxel

Ado-trastuzumab emtansine + Capecitabine

Ado-trastuzumab emtansine + Pertuzumab

Age Groups: senior | child | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.